Xcout Intel
IKAIKA THERAPEUTICS, INC.
Ikaika Therapeutics is a biotechnology company developing first-in-class anti-fibrotic biologic therapies for patients with fibrotic diseases, including muscular dystrophy. The company's lead technology utilizes antibodies, such as IKN-001, to inhibit the activation of transforming growth factor-beta (TGF-beta) by protecting latent TGF-beta binding protein 4 (LTBP4) from protease cleavage.
Subscribe to see IKAIKA THERAPEUTICS, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
IKAIKA THERAPEUTICS, INC. at a glance
IKAIKA THERAPEUTICS, INC. is a biotechnology company headquartered in United States. It has raised at least $2M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $1M in October 2021. Xcout tracks 4 named people at IKAIKA THERAPEUTICS, INC., including Alexis Demonbreun (CSO).
IKAIKA THERAPEUTICS, INC. leadership
- Alexis DemonbreunCSO
- Dimitra GeorganopoulouCBO
- Elizabeth McNallyCEO & Board Member
- CHIH-KAO HUDirector
IKAIKA THERAPEUTICS, INC. funding rounds
At least $2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1M | — | |
| VC Round | $1M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
IKAIKA THERAPEUTICS, INC. competitors
A few of IKAIKA THERAPEUTICS, INC.'s closest competitors — see the full list of competitors and alternatives →
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
4F Biotech is a biotechnology firm focused on developing innovative therapeutic approaches, screening platforms, and diagnostic tools to combat fibrosis and inflammatory processes.
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Get IKAIKA THERAPEUTICS, INC.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on IKAIKA THERAPEUTICS, INC. in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access